JP7204729B2 - 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 - Google Patents

新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 Download PDF

Info

Publication number
JP7204729B2
JP7204729B2 JP2020500863A JP2020500863A JP7204729B2 JP 7204729 B2 JP7204729 B2 JP 7204729B2 JP 2020500863 A JP2020500863 A JP 2020500863A JP 2020500863 A JP2020500863 A JP 2020500863A JP 7204729 B2 JP7204729 B2 JP 7204729B2
Authority
JP
Japan
Prior art keywords
amino acid
mutants
mutant
acid residues
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507676A (ja
Inventor
スンジェ パク
ヘシン チョン
スンジュ イ
ソナ ユ
ヒョンナム ソン
チャンウ イ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alteogen Inc
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of JP2021507676A publication Critical patent/JP2021507676A/ja
Priority to JP2022211105A priority Critical patent/JP2023052142A/ja
Application granted granted Critical
Publication of JP7204729B2 publication Critical patent/JP7204729B2/ja
Priority to JP2024159834A priority patent/JP2025004002A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020500863A 2018-07-25 2019-07-25 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 Active JP7204729B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022211105A JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2018-0086308 2018-07-25
KR20180086308 2018-07-25
KR10-2019-0029758 2019-03-15
KR20190029758 2019-03-15
PCT/KR2019/009215 WO2020022791A1 (ko) 2018-07-25 2019-07-25 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022211105A Division JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Publications (2)

Publication Number Publication Date
JP2021507676A JP2021507676A (ja) 2021-02-25
JP7204729B2 true JP7204729B2 (ja) 2023-01-16

Family

ID=69182377

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020500863A Active JP7204729B2 (ja) 2018-07-25 2019-07-25 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2022211105A Pending JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A Pending JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022211105A Pending JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A Pending JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Country Status (11)

Country Link
US (2) US12371683B2 (OSRAM)
EP (1) EP3636752A4 (OSRAM)
JP (3) JP7204729B2 (OSRAM)
KR (3) KR20210023798A (OSRAM)
CN (5) CN118853631A (OSRAM)
AU (2) AU2019311658B2 (OSRAM)
BR (1) BR112020019041A2 (OSRAM)
CA (1) CA3093885A1 (OSRAM)
MX (1) MX2020009824A (OSRAM)
RU (1) RU2766680C1 (OSRAM)
WO (1) WO2020022791A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
LT3130347T (lt) 2011-12-30 2019-10-25 Halozyme Inc Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
BR112021019076A2 (pt) * 2019-03-25 2021-11-30 Alteogen Inc Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana
CN120966799A (zh) * 2020-01-23 2025-11-18 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
KR20230041707A (ko) 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법
AU2021320569B2 (en) 2020-08-07 2024-10-03 Alteogen, Inc Method for producing recombinant hyaluronidase
US20220089738A1 (en) 2020-09-24 2022-03-24 Merck Sharp & Dohme Corp. Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CN115671267A (zh) 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
JP2024530152A (ja) 2021-08-02 2024-08-16 アルジェニクス ビーブイ 皮下単位剤形
WO2023042096A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
EP4424301A4 (en) * 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
CN114573715A (zh) * 2022-03-14 2022-06-03 江苏雅酶医药科技有限公司 一种重组长效人透明质酸酶及其生产方法和应用
JP2025513510A (ja) 2022-04-20 2025-04-24 アルトス バイオロジックス インク． オクレリズマブを含む薬学的組成物とその用途
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
WO2023249408A1 (ko) 2022-06-22 2023-12-28 (주)알테오젠 N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
CN119421949A (zh) * 2022-06-29 2025-02-11 奥德斯根株式会社 中性pH中显示活性的透明质酸酶Hyal1变体
WO2024025986A1 (en) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
CA3263055A1 (en) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) AND RHUPH20 ANTIBODIES OR VARIANTS OR FRAGMENTS THEREOF
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
AU2023410899A1 (en) 2022-12-22 2025-07-03 Halozyme, Inc. Hyaluronidase enzyme formulations for high volume administration
CN120936711A (zh) * 2023-03-23 2025-11-11 阿特根公司 新型透明质酸酶变体及包括其的药物组合物
KR20250086876A (ko) * 2023-12-06 2025-06-16 (주)한국비엠아이 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물
WO2025136032A1 (ko) * 2023-12-21 2025-06-26 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 hyal2 변이체
KR102896967B1 (ko) * 2023-12-21 2025-12-09 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 Hyal2 변이체
KR102875495B1 (ko) * 2023-12-28 2025-10-27 주식회사 오디스젠 히알루로니다제 Hyal1 변이체
CN119776311B (zh) * 2024-12-13 2025-12-19 江南大学 一种透明质酸合酶突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2015003167A1 (en) 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
WO2009037566A2 (en) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase and method of use thereof
ITMI20072225A1 (it) 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
PT4269578T (pt) 2008-03-06 2024-06-18 Halozyme Inc Produção em grande escala de hialuronidase solúvel
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
ES2573462T3 (es) 2008-12-09 2016-06-08 Halozyme, Inc. Polipéptidos de PH20 soluble extendida y usos de los mismos
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2010138918A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2477603B1 (en) * 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
BR112013032396A2 (pt) 2011-06-17 2016-11-22 Halozyme Inc formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
LT3130347T (lt) 2011-12-30 2019-10-25 Halozyme Inc Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
CN103173474B (zh) 2013-03-27 2014-08-27 广州白云山拜迪生物医药有限公司 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列
US9515094B2 (en) 2013-06-26 2016-12-06 Semiconductor Energy Laboratory Co., Ltd. Storage device and semiconductor device
MD20160061A2 (ro) 2013-11-13 2016-10-31 Tillotts Pharma Ag Sistem de livrare a medicamentului compus din particule multiple
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP6537076B2 (ja) 2014-07-31 2019-07-03 国立大学法人神戸大学 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
CN104745553B (zh) 2015-03-27 2017-11-28 杭州北斗生物技术有限公司 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
EP4516319A3 (en) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN105567606B (zh) 2016-03-02 2019-03-19 青岛海洋生物医药研究院股份有限公司 一种球形节杆菌及其产生的透明质酸酶
BR112019010947A2 (pt) 2016-11-30 2019-10-01 Univ Cornell nanopartículas ultrapequenas funcionalizadas por inibidores e métodos das mesmas
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
CA3058175A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
MX2021009975A (es) 2019-02-22 2021-12-10 Memorial Sloan Kettering Cancer Center Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
BR112021019076A2 (pt) * 2019-03-25 2021-11-30 Alteogen Inc Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana
JP2020197994A (ja) 2019-06-04 2020-12-10 東芝テック株式会社 情報処理装置及びその制御プログラム
CN120966799A (zh) 2020-01-23 2025-11-18 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
AU2021320569B2 (en) 2020-08-07 2024-10-03 Alteogen, Inc Method for producing recombinant hyaluronidase
US20220089738A1 (en) 2020-09-24 2022-03-24 Merck Sharp & Dohme Corp. Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
EP4424301A4 (en) 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2015003167A1 (en) 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
EP3636752A1 (en) 2020-04-15
US20210155913A1 (en) 2021-05-27
AU2023200324A1 (en) 2023-03-02
AU2019311658A8 (en) 2021-03-25
KR20210023798A (ko) 2021-03-04
JP2023052142A (ja) 2023-04-11
KR102151388B1 (ko) 2020-09-04
US12371683B2 (en) 2025-07-29
JP2021507676A (ja) 2021-02-25
MX2020009824A (es) 2021-01-15
KR20200017538A (ko) 2020-02-18
KR20250021616A (ko) 2025-02-13
CN118792283A (zh) 2024-10-18
RU2766680C1 (ru) 2022-03-15
AU2019311658A1 (en) 2021-02-11
JP2025004002A (ja) 2025-01-14
EP3636752A4 (en) 2021-04-28
CA3093885A1 (en) 2020-01-30
AU2023200324B9 (en) 2025-12-04
CN111971387A (zh) 2020-11-20
WO2020022791A1 (ko) 2020-01-30
CN118773171A (zh) 2024-10-15
CN118755703A (zh) 2024-10-11
BR112020019041A2 (pt) 2021-02-09
AU2023200324B2 (en) 2025-09-04
US20250368976A1 (en) 2025-12-04
CN118853631A (zh) 2024-10-29
AU2019311658B2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
JP7204729B2 (ja) 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
KR102801434B1 (ko) 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
KR20240110541A (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
KR20250162568A (ko) 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
RU2811464C2 (ru) Новые варианты гиалуронидазы с улучшенной стабильностью и содержащая их фармацевтическая композиция

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204729

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250